Mitochondrial DNA Replication, Disease-Associated Variants, and High-Fidelity Enzymatic Assay Reagents for Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for POLG drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Catalytic Subunit | POLG Recombinant Protein (Catalytic Domain) — High purity (>95%), Sequence Verified, Theoretical MW confirmed by MS. | View POLG Products |
| Disease Variants | POLG Mutant Proteins (A467T, W748S, R943H, etc.) — Pathogenic variants for mechanism and resistance studies. Endotoxin controlled. | View POLG Products |
| Complex Partner | POLG2 Recombinant Protein (Accessory Subunit) — For heterotrimeric processivity complex reconstitution. HEK293 expressed. | View POLG2 Products |
| Gene Delivery | POLG Lentivirus Particles — Full-length ORF with mitochondrial targeting sequence for stable cell lines. | View POLG Products |
| Validator | POLG siRNA Set — For knockdown verification and specificity controls in mtDNA replication assays. | View POLG Products |
| Replisome Component | TFAM Recombinant Protein — Mitochondrial transcription factor A for replication fork stabilization and mtDNA packaging. | View TFAM Products |
| Helicase Partner | TWNK (Twinkle) Recombinant Protein — Mitochondrial DNA helicase for unwinding assays and replisome reconstitution. | View TWNK Products |
| Related Target | POLRMT Recombinant Protein — Synergistic mitochondrial oncology target for transcription-coupled replication studies. | View POLRMT Products |
Critical Assay Challenges & TarMart Technical Specs
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial Import Sequence Functionality | Full-length POLG with intact MTS (Met1–Gln123) vs. catalytic domain (Ser124–Gln1239) options available; HEK293 expressed. |
| Polymerase Fidelity & Activity Measurement | High purity (>95%) recombinant proteins with minimal nuclease contamination for accurate error-rate and k_cat determination. |
| Processivity Complex Reconstitution | POLG + POLG2 heterotrimer validated at calibrated 1:2 stoichiometry; SSBP1-compatible formulations. |
| Disease Variant & Mutant Panel Integrity | Pathogenic mutants (A467T, W748S, R943H) with confirmed solubility and aggregation status; >95% purity, endotoxin <1 EU/µg. |
| Selectivity Profiling vs. Nuclear Polymerases | High-purity WT POLG for enzymatic panels against POLA, POLD, POLE; polymerase and exonuclease activity measured. |
| Antiviral Counter-Screening (Mitochondrial Toxicity) | Full-length recombinant POLG (high purity) for in vitro off-target inhibition kinetics (NRTI safety optimization). |
Live POLG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
POLG (DNA polymerase gamma) occupies a unique dual role in drug discovery. Historically, POLG was considered a critical anti-target: avoiding inhibition by nucleoside reverse transcriptase inhibitors (NRTIs) was paramount to preventing severe mitochondrial toxicity in HIV and HBV therapy. Today, the landscape has expanded. In oncology, aggressive tumors dependent on oxidative phosphorylation (OXPHOS) become vulnerable to targeted POLG inhibition, creating a synthetic lethality opportunity. Meanwhile, congenital POLG mutations cause devastating mitochondrial depletion syndromes (Alpers syndrome, progressive external ophthalmoplegia), driving gene therapy and small-molecule chaperone approaches. The next wave of R&D focuses on developing highly specific mitochondrial replisome inhibitors for cancer while sparing non-target tissues, alongside AAV-based gene therapy vectors for organ-specific restoration of wild-type polymerase activity. Allosteric modulators targeting the POLG–POLG2 interface represent an emerging modality for rare disease.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | AstraZeneca, Mitobridge, Gilead | Solid Tumors (mtDNA depletion strategy); AML | High-throughput polymerase activity assay with nuclease-free, high-purity recombinant POLG |
| Nucleoside/Nucleotide Analogs (Safety-Optimized) | Gilead, Merck, ViiV Healthcare | HIV, HBV (toxicity evaluation) | Enzymatic counter-screening: kinetic inhibition assay with full-length POLG and polymerase/exonuclease activity |
| Gene Therapy (AAV/Lentivirus) | Stealth BioTherapeutics, Astellas, academic consortia | Alpers syndrome, PEO, POLG-related ataxia | Functional rescue assay: disease-specific mutant proteins as negative controls; high-titer lentivirus for stable line generation |
| Allosteric Modulators | Biotonix, rare disease biotechs | Mitochondrial DNA depletion syndromes | Processivity assay with POLG–POLG2 heterotrimer (need stoichiometrically pure complex components) |
| Mutant Protein Rescue (Chaperone) | Rare disease consortia | Alpers syndrome, CPEO | Stability and compound-binding assays using pathogenic mutant panel (A467T, W748S, etc.) |